We excluded patients with viral hepatitis and other concomitant liver diseases. The XL probe was used in case M probe measurements failed because of obesity. Hepatic steatosis was graded by CAP using the M probe according to published cutoffs (S1=222-232; S2=233-289; S3=290 dB/m or above). Probe-specific cutoffs were used to define F3-4 and F4. We followed the manufacturer’s reliability

criteria based on the number of valid acquisitions and the interquartile range (IQR)-to-median ratio. Results: 2080 patients (45.4% women) find more completed the examination. M probe measurements were successful in 1927 (92.6%) patients, and the mean CAP was 262±65 dB/m (IQR 216-313). 1402 patients had fatty liver (72.8%; 95% CI 70.8-74.7). The number of patients with S1, S2 and S3 was 96 (5.0%), 574 (29.8%) and 732 (38.0%), respectively. LS by M probe

were reliable in 1908 of 2080 (91.7%) patients, and the mean LS was 7.5±5.3 kPa (IQR 4.8-8.2). A further 123 patients underwent XL probe examination and had reliable LS which was 9.2±10.0 kPa (IQR 4.4-9.5). Combining the reliable results by either probe in 2031 (97.6%) patients, 348 (17.1%, 95% CI 15.5-18.8%) had F3-4 and 233 (11.5%, 95% CI 10.1-12.9%) had F4. F4 was found in 4.8%, 6.3%, 7.0% and 18.9% of patients with S0, S1, S2 and S3, respectively (P<0.001). Conclusions: Patients with type 2 diabetes have a high prevalence of fatty liver and cirrhosis. Our data support fatty liver and fibrosis screening in this high-risk group. [This work was substantially supported by a grant DNA Damage inhibitor from the Research Grants Council of Hong Kong (Project no. CUHK 477813).] Disclosures: Grace LH Wong – Advisory Committees or Review Panels: Otsuka, Gilead; Speaking and Teaching: Echosens, Furui, Gilead, Janssen, Bristol-Myers Squibb, Otsuka Henry Lik-Yuen Chan – Advisory Committees or Review Panels: Gilead, MSD, Bristol-Myers Squibb, Roche, Novartis MCE公司 Pharmaceutical; Speaking and Teaching: Echosens, Abbvie Vincent

W. Wong – Advisory Committees or Review Panels: Abbvie, Gilead; Consulting: Merck, NovaMedica; Speaking and Teaching: Gilead, Echosens The following people have nothing to disclose: Raymond Kwok, Juliana C. Chan, Alice P. Kong Background: Nonalcoholic steatohepatitis (NASH) is associated with an increased risk of cardiovascular disease (CVD) mortality following liver transplant (LT); however, predictors of these events are unknown. Aim: To assess predictors of post-LT CVD mortality in patients with NASH. Methods: A cohort of 5,469 adults with NASH who underwent first LT (excluding status 1) from 2/2002-12/2011 was identified in the Organ Procurement and Transplantation Network database. An independent physician panel reviewed recipient cause of death. Cox proportional hazard model and Kaplan-Meier method assessed CVD mortality, defined as primary cause of death from thromboembolism, arrhythmia, heart failure, myocardial infarction, cardiac arrest and/or stroke.